BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 35062255)

  • 1. Variable Normalization of Naïve CD4+ Lymphopenia and Markers of Monocyte and T Cell Activation over the Course of Direct-Acting Anti-Viral Treatment of Chronic Hepatitis C Virus Infection.
    Auma AWN; Shive CL; Kostadinova L; Anthony DD
    Viruses; 2021 Dec; 14(1):. PubMed ID: 35062255
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Naïve CD4+ T Cell Lymphopenia and Apoptosis in Chronic Hepatitis C Virus Infection Is Driven by the CD31+ Subset and Is Partially Normalized in Direct-Acting Antiviral Treated Persons.
    Auma AWN; Shive CL; Lange A; Damjanovska S; Kowal C; Zebrowski E; Pandiyan P; Wilson B; Kalayjian RC; Canaday DH; Anthony DD
    Front Immunol; 2021; 12():641230. PubMed ID: 33912168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatitis C Virus (HCV) Direct-Acting Antiviral Therapy in Persons With Human Immunodeficiency Virus-HCV Genotype 1 Coinfection Resulting in High Rate of Sustained Virologic Response and Variable in Normalization of Soluble Markers of Immune Activation.
    Anthony DD; Sulkowski MS; Smeaton LM; Damjanovska S; Shive CL; Kowal CM; Cohen DE; Bhattacharya D; Alston-Smith BL; Balagopal A; Wyles DL
    J Infect Dis; 2020 Sep; 222(8):1334-1344. PubMed ID: 32406487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modifications of CD4 T cells, CD4/CD8 ratio and serum levels of soluble CD14 in HIV-HCV-coinfected patients after sustained HCV response induced by direct-acting antiviral agents: influence of liver cirrhosis.
    Girón-Ortega JA; Márquez-Coello M; Gutiérrez-Saborido D; Arizcorreta A; Cuesta-Sancho S; Girón-González JA
    Eur J Clin Microbiol Infect Dis; 2021 Sep; 40(9):1863-1871. PubMed ID: 33822285
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunological recovery in T-cell activation after sustained virologic response among HIV positive and HIV negative chronic Hepatitis C patients.
    Emmanuel B; El-Kamary SS; Magder LS; Stafford KA; Charurat ME; Poonia B; Chairez C; McLaughlin M; Hadigan C; Masur H; Kottilil S
    Hepatol Int; 2019 May; 13(3):270-276. PubMed ID: 30835046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Direct-acting antiviral therapy enhances total CD4+ and CD8+ T-cells responses, but does not alter T-cells activation among HCV mono-infected, and HCV/HIV-1 co-infected patients.
    Najafi Fard S; Schietroma I; Corano Scheri G; Giustini N; Serafino S; Cavallari EN; Pinacchio C; De Girolamo G; Ceccarelli G; Scagnolari C; Vullo V; d'Ettorre G
    Clin Res Hepatol Gastroenterol; 2018 Sep; 42(4):319-329. PubMed ID: 29279268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sustained virological response after treatment with direct antiviral agents in individuals with HIV and hepatitis C co-infection.
    Lodi S; Klein M; Rauch A; Epstein R; Wittkop L; Logan R; Rentsch CT; Justice AC; Touloumi G; Berenguer J; Jarrin I; Egger M; Puoti M; D'Arminio Monforte A; Gill J; Salmon Ceron D; van Sighem A; Linas B; van der Valk M; Hernán MA;
    J Int AIDS Soc; 2022 Dec; 25(12):e26048. PubMed ID: 36562643
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term evolution in liver fibrosis and immune profile after direct-acting antivirals therapy in hepatitis C virus-human immunodeficiency virus co-infected patients.
    Laguno M; Martínez-Rebollar M; Casanova M; de Lazzari E; González-Cordón A; Torres B; Inciarte A; Mora L; Ugarte A; Ambrosioni J; Blanco JL; Martínez E; Mallolas J
    Clin Microbiol Infect; 2022 Apr; 28(4):610.e1-610.e7. PubMed ID: 34464735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiviral therapy for HCV in hemophilia A patients with HIV-1 co-infection.
    Xiao H; Chen J; Wang J; Li J; Yang F; Lu H
    Medicine (Baltimore); 2019 Jul; 98(30):e16524. PubMed ID: 31348267
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive factors of hepatitis C virus eradication after interferon-free therapy in HIV coinfection.
    Domínguez-Domínguez L; Bisbal O; Matarranz M; Lagarde M; Pinar Ó; Hernando A; Lumbreras C; Rubio R; Pulido F
    Eur J Clin Microbiol Infect Dis; 2019 Apr; 38(4):725-734. PubMed ID: 30687869
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human Immunodeficiency Virus (HIV) Infection Is Associated With Lower Risk of Hepatocellular Carcinoma After Sustained Virological Response to Direct-acting Antivirals in Hepatitis C Infected Patients With Advanced Fibrosis.
    Corma-Gómez A; Macías J; Lacalle-Remigio JR; Téllez F; Morano L; Rivero A; Serrano M; Ríos MJ; Vera-Méndez FJ; Alados JC; Real LM; Palacios R; Santos IL; Imatz A; Pineda JA;
    Clin Infect Dis; 2021 Oct; 73(7):e2109-e2116. PubMed ID: 32766891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In Chronic Hepatitis C Infection, Myeloid-Derived Suppressor Cell Accumulation and T Cell Dysfunctions Revert Partially and Late After Successful Direct-Acting Antiviral Treatment.
    Telatin V; Nicoli F; Frasson C; Menegotto N; Barbaro F; Castelli E; Erne E; Palù G; Caputo A
    Front Cell Infect Microbiol; 2019; 9():190. PubMed ID: 31259160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liver Stiffness at the Time of Sustained Virological Response Predicts the Clinical Outcome in People Living With Human Immunodeficiency Virus and Hepatitis C Virus With Advanced Fibrosis Treated With Direct-acting Antivirals.
    Corma-Gómez A; Macías J; Téllez F; Freyre-Carrillo C; Morano L; Rivero-Juárez A; Ríos MJ; Alados JC; Vera-Méndez FJ; Merchante N; Palacios R; Granados R; Merino D; De Los Santos I; Pineda JA
    Clin Infect Dis; 2020 Dec; 71(9):2354-2362. PubMed ID: 31754695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased peripheral CD4
    Langhans B; Nischalke HD; Krämer B; Hausen A; Dold L; van Heteren P; Hüneburg R; Nattermann J; Strassburg CP; Spengler U
    J Hepatol; 2017 May; 66(5):888-896. PubMed ID: 28040549
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful DAA therapy for chronic hepatitis C reduces HLA-DR on monocytes and circulating immune mediators: A long-term follow-up study.
    Rosário NF; Saraiva GDN; Medeiros T; Gandini M; Lacerda G; Leite PEC; Andrade TG; Azeredo EL; Xavier AR; Silva AA
    Immunol Lett; 2020 Dec; 228():15-23. PubMed ID: 32946919
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HIV infection does not increase the risk of liver complications in hepatitis C virus-infected patient with advanced fibrosis, after sustained virological response with direct-acting antivirals.
    Corma-Gómez A; Morano L; Téllez F; Rivero-Juárez A; Real LM; Alados JC; Ríos-Villegas MJ; Vera-Méndez FJ; Muñoz RP; Geijo P; Macías J; Pineda JA;
    AIDS; 2019 Jun; 33(7):1167-1174. PubMed ID: 30845068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Both Hepatitis C Virus-Specific T Cell Responses and IL28B rs12979860 Single-Nucleotide Polymorphism Genotype Influence Antihepatitis C Virus Treatment Outcome in Patients with Chronic Hepatitis C.
    Benito JM; García-Samaniego J; García M; Madejón A; Martín-Carbonero L; Cabello A; Álvarez B; Górgolas M; Rallón N
    J Interferon Cytokine Res; 2017 Jun; 37(6):278-286. PubMed ID: 28440692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liver Fibrosis in Human Immunodeficiency Virus (HIV)-Hepatitis C Virus (HCV) Coinfection Before and After Sustained Virologic Response: What Is the Best Noninvasive Marker for Monitoring Regression?
    Kronfli N; Young J; Wang S; Cox J; Walmsley S; Hull M; Cooper C; Martel-Laferriere V; Wong A; Pick N; Klein MB;
    Clin Infect Dis; 2021 Aug; 73(3):468-477. PubMed ID: 32504083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of treatment with direct-acting antivirals on inflammatory markers and autoantibodies in HIV/HCV co-infected individuals.
    Rossotti R; Merli M; Baiguera C; Bana NB; Rezzonico LF; D'Amico F; Raimondi A; Moioli MC; Chianura LG; Puoti M
    J Viral Hepat; 2023 Jun; 30(6):530-539. PubMed ID: 36773329
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HCV Cure With Direct-Acting Antivirals Improves Liver and Immunological Markers in HIV/HCV-Coinfected Patients.
    Brochado-Kith Ó; Martínez I; Berenguer J; González-García J; Salgüero S; Sepúlveda-Crespo D; Díez C; Hontañón V; Ibañez-Samaniego L; Pérez-Latorre L; Fernández-Rodríguez A; Ángeles Jiménez-Sousa M; Resino S
    Front Immunol; 2021; 12():723196. PubMed ID: 34497613
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.